Evaluation of novel 7-(hetero)aryl-substituted pyrazolo[1, 5-a]pyrimidines as phosphodiesterase-4 inhibitors

Letters in Drug Design and Discovery

Volumn 7, Issue 6, 2010, Pages 402-408

  Kodimuthali Arumugam, A ^a,b   Gupta, Rajesh ^a   Parsa, Kishore Venkata Laxmi ^a   Prasunamba, Padala Lakshmi ^b   Pal, Manojit ^a  

^a Matrix Laboratories Limited   (India)

^b OSMANIA UNIVERSITY   (India)

Author keywords

Inhibitor; PDE4; Pyrazolopyrimidine; Rolipram

Indexed keywords

7 CHLORO 5 PHENYLPYRAZOLO[1,5 A]PYRIMIDINE; ALUMINUM CHLORIDE; CARBON; HETEROARENE DERIVATIVE; PHOSPHODIESTERASE IV INHIBITOR; POLYCYCLIC AROMATIC HYDROCARBON DERIVATIVE; PYRAZOLO[1, 5 A]PYRIMIDINE DERIVATIVE; PYRIMIDINE DERIVATIVE; ROLIPRAM; UNCLASSIFIED DRUG;

ARTICLE; CHEMICAL BOND; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG SCREENING; DRUG SYNTHESIS; EMBRYO; ENZYME INHIBITION; HUMAN; HUMAN CELL; IN VITRO STUDY; PRIORITY JOURNAL;

EID: 77954808061     PISSN: 15701808     EISSN: None     Source Type: Journal    
DOI: 10.2174/157018010791306542     Document Type: Article

References (27)

1. Kodimuthali, A.; Jabaris, S.; Pal, M. Recent advances on phos-phodiesterase 4 inhibitors for the treatment of asthma and chronic obstructive pulmonary disease. J. Med. Chem., 2008, 51, 5471-5489.
2. Houslay, M.D.; Schafer, P.; Zhang, K.Y.J. Phosphodiesterase-4 as a therapeutic target. Drug Discov. Today, 2005, 10, 1503-1519.
3. Burnouf, C.; Pruniaux, M.-P. Recent advances in PDE4 inhibitors as immunoregulators and anti-inflammatory drugs. Curr. Pharm. Design, 2002, 8, 1255-1296.
4. Barnes, P.J.; Stockley, R.A. COPD: current therapeutic interventions and future approaches. Eur. Respir. J., 2005, 25, 1084-1106.
5. Soto, F.J.; Hanania, N.A. Selective phosphodiesterase-4 inhibitors in chronic obstructive lung disease. Curr. Opin. Pulm. Med., 2005, 11, 129-134.
6. Lipworth, B.J. Phosphodiesterase-4 inhibitors for asthma and chronic obstructive pulmonary disease. Lancet, 2005, 365, 167-175.
7. Odingo, J.O. Inhibitors of PDE4: a review of recent patent literature. Expert Opin. Ther. Patents, 2005, 15, 773-787.
8. Smith, V.B.; Spina, D. Selective phosphodiesterase 4 inhibitors in the treatment of allergy and inflammation. Curr. Opin. Invest. Drugs, 2005, 6, 1136-1141.
9. Rao, Y.J.; Xi, L. Pivotal effects of phosphodiesterase inhibitors on myocyte contractility and viability in normal and ischemic hearts. Acta Pharmacol. Sin., 2009, 30, 1-24.
10. Ma, D.; Wu, P.; Egan, R.W.; Billah, M.M.; Wang, P. Phosphodiesterase 4B gene transcription is activated by lipopolysaccharide and inhibited by interleukin-10 in human monocytes. Mol. Pharmacol, 1999, 55, 50-57.
11. Jin, S.L.; Lan, L.; Zoudilova, M.; Conti, M. Specific role of phosphodiesterase 4B in lipopolysaccharide induced signaling in mouse macrophages. J. Immunol., 2005, 175, 1523-1531.
12. Robichaud, A.; Stamatiou, P.B.; Jin, S.L.; Lachance, N.; Mac-Donald, D.; Laliberté, F.; Liu, S.; Huang, Z.; Conti, M.; Chan, C.C. Deletion of phosphodiesterase 4D in mice shortens alpha(2)-adrenoceptor-mediated anesthesia, a behavioral correlate of emesis. J. Clin. Invest., 2002, 110, 1045-1052.
13. Gibson, L.C.; Hastings, S.F.; McPhee, I.; Clayton, R.A., Darroch, C.E.; Mackenzie, A.; Mackenzie, F.L.; Nagasawa, M.; Stevens, P.A.; Mackenzie, S.J. The inhibitory profile of ibudilast against the human phosphodiesterase enzyme family. Eur. J. Pharmacol., 2006, 538, 39-42.
14. Huang, Z.; Liu, S.; Zhang, L.; Salem, M.; Greig, G.M.; Chan, C.C.; Natsumeda, Y.; Noguchi, K. Preferential inhibition of human phosphodiesterase 4 by ibudilast. Life Sci., 2006, 78, 2663-2668.
15. Ochiai, H.; Ishida, A.; Ohtani, T.; Kusumi, K.; Kishikawa, K.; Yamamoto, S.; Takeda, H.; Obata, T.; Nakaia, H.; Toda, M. New orally active PDE4 inhibitors with therapeutic potential. Bioorg. Med. Chem., 2004, 12, 4089-4100.
16. Allen, D.G.; Coe, D.M.; Cook, C.M.; Dowle, M.D.; Edlin, C.D.; Hamblin, J.N.; Johnson, M.R.; Jones, P.S.; Lindvall, M.K.; Mitchell, C.J.; Redgrave, A.J.; Robinson, J.E.; Trivedi, N. Pyazolo[3,4-b]pyridine compounds, and their use as PDE4 inhibitors. U.S. Pat. Appl. US 2008/0132536 A1, June 5, 2008.
17. Hamblin, J.N.; Angell, T.D.R.; Ballantine, S.P.; Cook, C.M.; Cooper, A.W.J.; Dawson, J.; Delves, C.J.; Jones, P.S.; Lindvall, M.; Lucas, F.S.; Mitchell, C.J.; Neu, M.Y.; Ranshaw, L.E.; Solanke, Y.E.; Somers, D.O.; Wiseman, J.O. Pyrazolopyridines as a novel structural class of potent and selective PDE4 inhibitors. Bioorg. Med. Chem. Lett., 2008, 18, 4237-4241.
18. Gopalan, B.; Pal, M.; Havale, S.; Arumugam, K.; Sing, S.K.; Gupta, R.V.; Tokala, R.K.; Mungara, A.; Chary, B.C.; George, S.L.J.S. Novel heterocyclic compounds, pharmaceutical compositions containing them and processes for their preparation. World Pat. Appl., WO 2009/115874 A2, 24 September 2009.
19. George, S.L.J.S.; Gupta, R.V.; Manne, N.K.; Sreelatha, V.; Pal, M.; Singh, S.K.; Havale, S.H.; Kodimuthali, A.; Venkata, L.K.P. Novel PDE inhibitors, pharmaceutical compositions containing them and process for their preparation. World Pat. Appl., WO 2009/147476 A1, 10 December 2009.
20. Kodimuthali, A.; Nishad, T.C.; Prasunamba, P.L.; Pal, M. Reactivity of the -C(Cl)=C-C=N- moiety towards AlCl3-induced C-C bond forming reactions: a new synthesis of 7-(hetero)aryl-substituted pyrazolo[1,5-a]pyrimidines. Tetrahedron Lett., 2009, 50, 354-358.
21. Bora, R.S.; Malik, R.; Arya, R.; Gupta, D.; Singh, V.; Aggarwal, N.; Dastidar, S.; Ray, A.; Saini, K.S. A reporter gene assay for screening of PDE4 subtype selective inhibitors. Biochem. Biophy. Res. Comm., 2007, 356, 153-158.
22. Demnitz, J.; LaVecchia, L.; Bacher E.; Keller T.H.; Muller, T.; Schurch, F.; Weber, H. P.; Pombo-Villar, E. Enantiodivergent synthesis of (R)- and (S)- rolipram. Molecules, 1998, 3, 107-119.
23. Xu, R.X.; Hassell, A.M.; Vanderwall, D.; Lambert, M.H.; Holmes, W.D.; Luther, M.A.; Rocque, W.J.; Milburn, M.V.; Zhao, Y.; Ke, H.; Nolte, R.T. Atomic structure of PDE4: insights into phosphodi-esterase mechanism and specificity. Science, 2000, 288, 1822-1825.
24. Zhang, K.Y.J.; Card, G.L.; Suzuki, Y.; Artis, D.R.; Fong, D.; Gillette, S.; Hsieh, D.; Neiman, J.; West, B.L.; Zhang, C.; Milburn, M.V.; Kim, S.-H.; Schiessinger, J.; Bollag, G. A glutamine switch mechanism for nucleotide selectivity by phosphodiesterases. Mol. Cell, 2004, 15, 279-286.
25. Huai, Q.; Wang, H.; Sun, Y.; Kim, H.Y.; Liu, Y.; Ke, H. Three-dimensional structures of PDE4D in complex with roliprams and implication on inhibitor selectivity. Structure, 2003, 11, 865-873.
26. Manallack, D.T.; Hughes, R.A.; Thompson, P.E. The next generation of phosphodiesterase inhibitors: structural clues to ligand and substrate selectivity of phosphodiesterases. J. Med. Chem., 2005, 48, 3449-3462.
27. Wang, H.; Peng, M.S.; Chen, Y.; Geng, J.; Robinson, H.; Houslay, M.D.; Cai, J.; Ke, H. Structures of the four subfamilies of phosphodiesterase-4 provide insight into the selectivity of their inhibitors. Biochem. J., 2007, 408, 193-201.